Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.55 |
| ▸ | KDR | P35968 | 8/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.55 |
| ▸ | JAK3 | P52333 | 5/20 | 0.55 |
| ▸ | BRAF | P15056 | 5/20 | 0.54 |
| ▸ | TEK | Q02763 | 4/20 | 0.53 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 2/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263470 | 0.89 | LCK (0.69) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL2262925 | 0.85 | LCK (0.51) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL11889165 | 0.83 | BRAF (0.58) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL2265281 | 0.81 | LCK (0.70) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL11889222 | 0.80 | LCK (0.54) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL2268814 | 0.80 | LCK (0.55) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL2264973 | 0.79 | LCK (0.55) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL2263097 | 0.78 | LCK (0.69) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL12230802 | 0.78 | LCK (0.57) | LCKKDRMAPK14JAK3BRAF | |
| SCHEMBL11889207 | 0.78 | LCK (0.58) | LCKKDRMAPK14JAK3BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976836-B9 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |